Clarify regulatory uncertainties with the MHRA and US FDA at SMi's 13th annual Controlled Release conference
SMi's 13th annual Controlled Release conference, taking place on 18-19 April 2016 in London, will feature case studies and project updates from leading regulatory bodies and global pharmaceutical companies.
- (1888PressRelease) February 18, 2016 - This year's Controlled Release conference is the only industry event which will feature the MHRA and US FDA clarifying your regulatory uncertainties, in addition to providing you with updates from your industry colleagues on the latest innovations to accelerate commercialisation, as well as developments in the regulatory landscape to ensure strict compliance. The two-day programme is packed with unmissable case studies from global pharma companies including GlaxoSmithKline, Ipsen, Novo Nordisk, MedImmune, AstraZeneca, Lundbeck, Merck, UCB Pharma, Critical Pharmaceuticals, Kashiv Pharma and Diurnal:
• The importance of QbD
GSK examines how Quality by Design (QbD) can aid formulation and controlled release delivery
Novo Nordisk demonstrates application of QbD during spray drying scale-up
• Innovations in Controlled Release
MedImmune talks about controlling peptide stability to unlock therapeutic potential
AstraZeneca presents nanomedicine design for controlled release
• Product Design
Parenteral controlled release: Revival for increased adherence - case study by Merck
Lundbeck showcases how to formulate poorly soluble drugs
• New platforms in Controlled Release delivery
CriticalMix platform technology: A novel platform technology for sustained delivery of small and large APIs by Critical Pharmaceuticals
Diurnal on optimising drug delivery systems to mimic the human circadian rhythm
To view the full speaker line-up and conference programme, visit http://www.controlledrelease.co.uk/1888pressrelease
Plus, don't miss the two post-conference workshops taking place on 20th April 2016 in London, UK:
Workshop A: QbD/PAT Driven Controlled Release Design and Development
Hosted by by Daniela Stranges, Senior Scientist, Quality by Design Integration, GlaxoSmithKline and Jerome Mantanus, Senior Scientist QbD/PAT Drug Product Formulation, UCB Pharma
Workshop B: Exploring Controlled Release Drug Delivery Methods
Hosted by Rene Holm, Senior Director, Lundbeck; Clive Wilson, Professor of Pharmaceutics, University of Strathclyde; Ijeoma Uchegbu, Scientific Secretary CRS, Chair in Pharmaceutical Nanoscience, University of London and CEO, Nanometrics
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam